TABLE 1.
Baseline characteristics
| Variable | Dataa |
|---|---|
| Age (mean ± SD) (yr) | 50.58 ± 18.27 |
| Gender | |
| Women | 226 (51.6) |
| Men | 212 (48.4) |
| Elapsed time between OS & AVT (days)b | |
| ≤2 | 195 (44.5) |
| >2 and ≤7 | 191 (43.6) |
| >7 | 47 (10.7) |
| Missing data | 5 (1.1) |
| Glasgow Coma Scale score (median [IQR]) | 14 (13–15) |
| New-onset convulsionc | |
| No | 343 (78.3) |
| Yes | 91 (20.8) |
| Missing data | 4 (0.9) |
| Immunosuppressiond | |
| No | 379 (86.5) |
| Yes | 59 (13.5) |
| Outcome | |
| Favorable | 206 (47.0) |
| Unfavorable | 232 (53.0) |
| Died | 44 (10.0) |
| Survived with severe sequela(e) | 188 (42.9) |
a
Values are no. (%) of patients, unless otherwise indicated. Total n = 438.
b
Elapsed time between onset of symptoms (OS) and the start of antiviral treatment (AVT).
c
Defined as a convulsion observed before therapy.
d
Defined as long-term steroid use or other immunosuppressive state.